| Literature DB >> 30144521 |
Alan J Wigg1, Rachel Wundke2, Rosemary McCormick2, Kate R Muller2, Jeyamani Ramachandran2, Sumudu K Narayana2, Richard J Woodman3.
Abstract
Patients with cirrhosis have increased morbidity from hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, and vaccination against these infections is an important standard of care.1,2 However, vaccination in patients with cirrhosis is hindered by immune dysfunction and there is limited high-quality literature available. The aim of this work therefore was to compare immune responses of standard dose (SD) with high-dose accelerated (HDA) vaccination in cirrhotic patients.Entities:
Year: 2018 PMID： 30144521 DOI： 10.1016/j.cgh.2018.08.047
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN： 1542-3565 Impact factor: 11.382